Geode Capital Management LLC Sells 9,027 Shares of Mural Oncology plc (NASDAQ:MURA)

Geode Capital Management LLC lowered its holdings in shares of Mural Oncology plc (NASDAQ:MURA) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 181,029 shares of the company’s stock after selling 9,027 shares during the quarter. Geode Capital Management LLC owned 1.06% of Mural Oncology worth $583,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Virtu Financial LLC bought a new position in shares of Mural Oncology in the 4th quarter valued at about $129,000. 80.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MURA. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research note on Tuesday, March 25th. HC Wainwright cut their target price on Mural Oncology from $18.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Morgan Stanley downgraded Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 25th. Finally, Raymond James cut shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price objective on the stock. in a research report on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Stock Performance

MURA opened at $2.64 on Friday. The stock’s 50 day moving average price is $2.57 and its 200-day moving average price is $3.31. Mural Oncology plc has a one year low of $0.95 and a one year high of $4.74. The stock has a market cap of $45.48 million, a price-to-earnings ratio of -0.29 and a beta of 5.28.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter in the prior year, the company earned ($3.57) earnings per share. As a group, analysts predict that Mural Oncology plc will post -7.54 earnings per share for the current fiscal year.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.